Clinical Trial Update: Short Course Daratumumab in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

This report summarizes Phase 2 results for a short-course daratumumab regimen in patients with multiple myeloma, with the trial completed and results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07